1. G.d. Searle & Company (23 from 1,323 patents)

2. Other (3 from 832,891 patents)

3. Astrazeneca Canada Inc. (3 from 14 patents)

4. Pfizer Corporation (1 from 4,455 patents)

5. Monsanto Company (1 from 3,288 patents)

6. Agouron Pharmaceuticals, Inc. (1 from 174 patents)

1. 7232817 - α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors

2. 7202258 - α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors

3. 7199158 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

4. 7037941 - Alpha-and Beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors

5. 7030161 - α-and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

6. 6951886 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

7. 6903132 - Non-peptide GnRH agents, pharmaceutical compositions and methods for their use

8. 6777561 - Compounds

9. 6683648 - &agr;- and &bgr;-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

10. 6515024 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

11. 6444678 - &agr;- and &bgr;-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors

12. 6403585 - &agr;-and &bgr;-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

13. 6387949 - Substituted urea compounds useful in pain management

14. 6376534 - Compounds useful in pain management

15. 6337398 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors